Literature DB >> 16980988

Mismatch of minor histocompatibility antigen contributes to a graft-versus-leukemia effect rather than to acute GVHD, resulting in long-term survival after HLA-identical stem cell transplantation in Japan.

T Katagiri1, S Shiobara, S Nakao, M Wakano, E Muranaka, N Kuba, T Furukawa, J Tsukada, H Takeda, Y Aizawa, M Harada.   

Abstract

We determined the alleles of five polymorphic molecules including HA-1 and four adhesion molecules for 106 patients transplanted with HLA-identical stem cell grafts and investigated the association of mismatches as correlates of relapse and graft-versus-host disease (GVHD). All 106 recipients underwent stem cell transplantation (SCT) after myeloablative conditioning between 1985 and 2002. Risk status of disease at SCT was standard (n=63) and high (n=42). After SCT, 36, 49 and 33 developed acute GVHD, chronic GVHD and relapsed, respectively. Our patients relapsed at rates of 16.7 and 38.6% with one or more and without incompatibilities (P=0.013). The relapse rates of patients with CD62L, CD31 codon 563, CD31 codon 125, HA-1 and CD49b incompatibilities were 5.9, 11.8, 15.4, 16.0 and 33.3%, respectively. The frequency of acute GVHD did not differ regardless of incompatibilities. In standard-risk group, the accumulated relapse rates of 19 and 44 patients with and without minor histocompatibility antigen incompatibility were 22% and unexpectedly 66%, respectively (P=0.02). The probability of 12-year survival was 88% in the former and 66% in the latter patients (P=0.03). Our data suggest that incompatibility of CD62L, CD31 codon 563 and CD31 codon 125 contributes to a graft-versus-leukemia effect rather than to GVHD, resulting in prolonged survival after HLA-identical SCT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980988     DOI: 10.1038/sj.bmt.1705506

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

Review 1.  Can we make a better match or mismatch with KIR genotyping?

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation.

Authors:  Marcelo A Fernandez-Viña; Tao Wang; Stephanie J Lee; Michael Haagenson; Mahmoud Aljurf; Medhat Askar; Minoo Battiwalla; Lee-Ann Baxter-Lowe; James Gajewski; Ann A Jakubowski; Susana Marino; Machteld Oudshoorn; Steven G E Marsh; Effie W Petersdorf; Kirk Schultz; E Victoria Turner; Edmund K Waller; Ann Woolfrey; John Umejiego; Stephen R Spellman; Michelle Setterholm
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

Review 3.  Allogeneic tumor cell vaccines: the promise and limitations in clinical trials.

Authors:  Sanjay Srivatsan; Jaina M Patel; Erica N Bozeman; Imade E Imasuen; Sara He; Danielle Daniels; Periasamy Selvaraj
Journal:  Hum Vaccin Immunother       Date:  2013-09-24       Impact factor: 3.452

Review 4.  Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT.

Authors:  Edus H Warren; Xinyi Cindy Zhang; Shuying Li; Wenhong Fan; Barry E Storer; Jason W Chien; Michael J Boeckh; Lue Ping Zhao; Paul J Martin; John A Hansen
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

5.  Occurrence and Impact of Minor Histocompatibility Antigens' Disparities on Outcomes of Hematopoietic Stem Cell Transplantation from HLA-Matched Sibling Donors.

Authors:  Monika Dzierzak-Mietla; M Markiewicz; Urszula Siekiera; Sylwia Mizia; Anna Koclega; Patrycja Zielinska; Malgorzata Sobczyk-Kruszelnicka; Slawomira Kyrcz-Krzemien
Journal:  Bone Marrow Res       Date:  2012-11-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.